Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • Why are fully vaccinated people testing positive for Covid?
    • Extreme weather takes climate change models ‘off the scale’
    • Tory jitters greet Johnson’s second anniversary as prime minister
    • South Africa counts the cost of its worst unrest since apartheid
    • ‘Even Brexit wasn’t this bad’: traffic-free schemes split neighbourhood
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Wall Street doubles down on lending ‘cheap money’ to the rich
    • China is defying US pressure to change its behaviour
    • China imposes sanctions on Wilbur Ross and six other Americans
    • Hangover strikes Wall Street after ‘epic’ Spac party
    • The horror scenario lurking in the plumbing of finance
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Wall Street doubles down on lending ‘cheap money’ to the rich
    • Regulators in three US states close in on BlockFi’s cryptocurrency accounts
    • Goldman and DWS prepare bids for NN Investment Partners
    • Male advertisers win sex discrimination case
    • Philip Morris to stop selling Marlboro cigarettes in UK within 10 years
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Hangover strikes Wall Street after ‘epic’ Spac party
    • The horror scenario lurking in the plumbing of finance
    • Wall Street stocks end volatile week at record high
    • Will the Fed give any clues on its timeline for slowing bond purchases?
    • Covid wobble punctures calm markets. Get used to it
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Mourning the expat city state
    • The life-long art of making friends
    • Unleash the ladybirds of war — controlling garden pests the natural way
    • Hangover strikes Wall Street after ‘epic’ Spac party
    • The horror scenario lurking in the plumbing of finance
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Employee data can be used for good, but treat it with care
    • Keeping staff and clients on board in a pandemic
    • Discrimination at work: ‘I was shocked when the interviewer ghosted me’
    • My skill set is underused, how do I break the cycle and excel?
    • Leaders’ love of offices is based on an outdated fantasy
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Mourning the expat city state
    • Seven gadgets for happy homes
    • The life-long art of making friends
    • Inside the ‘ghost’ distilleries that have risen from the dead
    • Unleash the ladybirds of war — controlling garden pests the natural way
  • How to Spend It
  • Sign In
  • Subscribe
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Hannah Kuchler

Global Pharmaceuticals Correspondent
Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Friday, 23 July, 2021
    Covid-19 vaccines
    US buys 200m Pfizer jabs for children and possible boosters

    New deal for Covid vaccinations comes amid debate over whether Delta variant requires third doses

  • Thursday, 22 July, 2021
    GlaxoSmithKline PLC
    GSK picks insider to run consumer health business after spin-off

    Brian McNamara will run business with annual sales of more than £10bn

  • Thursday, 22 July, 2021
    News in-depthCureVac GmbH
    ‘The race is on’: CureVac seeks answers to vaccine disappointment

    The mRNA pioneer was beaten by Moderna and BioNTech but is plotting a comeback

  • Wednesday, 21 July, 2021
    Novartis AG
    Novartis aims to beat rivals to novel $10bn cancer treatment market

    Trial results for new targeted therapy ‘pretty remarkable’, says CEO

  • Sunday, 18 July, 2021
    Health sector
    Soros and Gates back buyout of UK diagnostic technology group

    Mologic will be turned into a social enterprise for testing tropical diseases

  • Saturday, 17 July, 2021
    News in-depthCovid-19 vaccines
    Booster shot debate takes centre stage as global Covid cases rise

    There are calls in some quarters to give out third doses, but billions of people are still waiting for their first jab

  • Friday, 16 July, 2021
    GlaxoSmithKline PLC
    GSK to create up to 5,000 jobs as it plans huge biotech centre

    UK drugmaker seeks to unlock £400m of private investment for site in Stevenage

  • Thursday, 15 July, 2021
    Covid-19 vaccines
    Covax launches marketplace for Covid vaccine inputs to boost production

    Platform aims to match manufacturers with suppliers to address supply chain bottlenecks

  • Wednesday, 14 July, 2021
    Disease control and prevention
    Covid pandemic triggers drop in routine childhood vaccinations

    At least 23m children worldwide have missed jabs against other diseases, say WHO and Unicef

  • Promoted Content
  • Sunday, 27 June, 2021
    Pharmaceuticals sector
    Crispr gene-editing ‘revolution’ treats internal organ for first time

    US start-up co-founded by Nobel laureate marks breakthrough over therapies restricted to external cells

  • Wednesday, 23 June, 2021
    GlaxoSmithKline PLC
    GSK chief shrugs off concerns over leadership as she outlines vision

    Emma Walmsley insists she is a ‘change agent’ committed to transforming pharma group

  • Wednesday, 23 June, 2021
    FT News Briefing podcast10 min listen
    Will too many influencers kill Instagram?

    As millennials reach middle-age, Facebook’s prize app may be losing its money-making ability

  • Tuesday, 22 June, 2021
    Artificial intelligence
    AI drug discovery start-up Insilico raises more than $255m

    Hong Kong-based platform has 16 programmes in development including potential cancer and Covid treatments

  • Monday, 21 June, 2021
    Vaccitech
    Vaccitech chief confident of beating mRNA in cancer treatment

    Group behind AstraZeneca jab believes it has better chance of success in tackling tumours

  • Saturday, 19 June, 2021
    Health
    GSK faces struggle to convince investors as activist Elliott lurks

    Walmsley has questions to answer at roadshow over direction of pharma group’s future

  • Friday, 18 June, 2021
    AstraZeneca PLC
    EU fails in legal bid to speed up AstraZeneca vaccine supply

    Pharma group avoids billions in fines but court acknowledges ‘serious breach’ of contracts

  • Thursday, 17 June, 2021
    Covid-19 vaccines
    CureVac to press on with mRNA vaccine despite disappointing trials

    German drugmaker believes jab could still be used for some age groups or as booster

  • Tuesday, 15 June, 2021
    AstraZeneca PLC
    AstraZeneca Covid antibody treatment fails to hit main targets in latest trial

    Phase 3 stage shows drug not significantly more effective than placebo

  • Monday, 14 June, 2021
    Novavax Inc
    Novavax vaccine trial shows 90% efficacy in combating Covid-19

    Biotech ‘one step closer’ to launching shot but has yet to finalise regulatory submissions

  • Monday, 14 June, 2021
    GlaxoSmithKline PLC
    GSK lines up cancer treatment with US biotech deal

    UK pharma group will pay iTeos Therapeutics up to $2.1bn to collaborate on a tumour drug

  • Sunday, 13 June, 2021
    Drugs research
    Vaxxinity hopes its Covid jab technology will help treat Alzheimer’s

    US biotech says pandemic has helped it accelerate development of new class of drugs

  • Friday, 11 June, 2021
    GlaxoSmithKline PLC
    GSK consumer chief plans deal spree after split from pharma

    Head of division that sells vitamins and toothpaste reveals growth plan for soon-to-be independent business

  • Friday, 11 June, 2021
    The Big Read
    The Alzheimer’s economy: is the new $56,000-a-year drug worth it?

    US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high

  • Friday, 11 June, 2021
    Covid-19 vaccines
    The next generation Covid-19 vaccines seeking a slice of the market

    Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic

  • Thursday, 10 June, 2021
    The Big Read
    A king’s vaccine: Thailand’s struggle to deliver jabs to its people

    The company producing the AstraZeneca vaccine in the country is owned by the monarch and there are signs of delays in the politically-sensitive rollout

Previous You are on page 1 Next

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingContracts & TendersExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2021. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Graphics
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In